FY2029 Earnings Forecast for XENE Issued By Wedbush

Xenon Pharmaceuticals Inc. (NASDAQ:XENE) – Equities research analysts at Wedbush issued their FY2029 EPS estimates for Xenon Pharmaceuticals in a report issued on Thursday, January 23rd. Wedbush analyst L. Chico forecasts that the biopharmaceutical company will post earnings of $5.54 per share for the year. The consensus estimate for Xenon Pharmaceuticals’ current full-year earnings is ($3.13) per share.

Other equities analysts also recently issued reports about the stock. Needham & Company LLC reaffirmed a “buy” rating and set a $60.00 price objective on shares of Xenon Pharmaceuticals in a research note on Wednesday, November 13th. Raymond James reaffirmed an “outperform” rating and set a $50.00 price objective on shares of Xenon Pharmaceuticals in a research note on Thursday, October 10th. Finally, HC Wainwright reaffirmed a “buy” rating and set a $53.00 price objective on shares of Xenon Pharmaceuticals in a research note on Thursday, December 12th. Seven research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat, Xenon Pharmaceuticals presently has a consensus rating of “Buy” and a consensus target price of $56.00.

Xenon Pharmaceuticals Trading Down 0.1 %

Shares of NASDAQ:XENE opened at $39.95 on Friday. The company has a market cap of $3.05 billion, a price-to-earnings ratio of -14.17 and a beta of 1.20. The company has a 50-day moving average price of $40.20 and a 200-day moving average price of $40.82. Xenon Pharmaceuticals has a 12 month low of $35.53 and a 12 month high of $50.99.

Xenon Pharmaceuticals (NASDAQ:XENE) last issued its quarterly earnings data on Tuesday, November 12th. The biopharmaceutical company reported ($0.81) EPS for the quarter, beating the consensus estimate of ($0.82) by $0.01. During the same quarter in the prior year, the company earned ($0.73) EPS.

Institutional Investors Weigh In On Xenon Pharmaceuticals

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. FMR LLC grew its holdings in shares of Xenon Pharmaceuticals by 2.2% during the third quarter. FMR LLC now owns 6,917,684 shares of the biopharmaceutical company’s stock valued at $272,349,000 after buying an additional 149,511 shares during the last quarter. Driehaus Capital Management LLC grew its holdings in shares of Xenon Pharmaceuticals by 2.3% during the second quarter. Driehaus Capital Management LLC now owns 4,419,472 shares of the biopharmaceutical company’s stock valued at $172,315,000 after buying an additional 97,732 shares during the last quarter. Wellington Management Group LLP grew its holdings in shares of Xenon Pharmaceuticals by 0.4% during the third quarter. Wellington Management Group LLP now owns 3,843,447 shares of the biopharmaceutical company’s stock valued at $151,317,000 after buying an additional 15,226 shares during the last quarter. Braidwell LP grew its holdings in shares of Xenon Pharmaceuticals by 5.7% during the third quarter. Braidwell LP now owns 2,707,255 shares of the biopharmaceutical company’s stock valued at $106,585,000 after buying an additional 146,682 shares during the last quarter. Finally, Janus Henderson Group PLC grew its holdings in shares of Xenon Pharmaceuticals by 144.2% during the third quarter. Janus Henderson Group PLC now owns 2,552,392 shares of the biopharmaceutical company’s stock valued at $100,506,000 after buying an additional 1,507,135 shares during the last quarter. Hedge funds and other institutional investors own 95.45% of the company’s stock.

Insider Buying and Selling

In other Xenon Pharmaceuticals news, Director Gary Patou sold 4,891 shares of the company’s stock in a transaction dated Friday, November 22nd. The shares were sold at an average price of $41.08, for a total value of $200,922.28. Following the sale, the director now owns 23,573 shares in the company, valued at approximately $968,378.84. This represents a 17.18 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, CFO Sherry Aulin sold 18,709 shares of the company’s stock in a transaction dated Wednesday, December 18th. The stock was sold at an average price of $41.21, for a total transaction of $770,997.89. The disclosure for this sale can be found here. 5.52% of the stock is owned by insiders.

About Xenon Pharmaceuticals

Xenon Pharmaceuticals Inc, a neuroscience-focused biopharmaceutical company, engages in the development of therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN1101, a novel and potent Kv7 potassium channel opener, which is in Phase 3 clinical trials for the treatment of epilepsy and other neurological disorders.